CAM-TRT 1

CAM-TRT 1 is a preclinical-stage targeted radiotherapeutic being developed by Precirix. The drug candidate utilizes a single-domain antibody (sdAb), also known as a nanobody, to deliver a therapeutic radioisotope to specific cellular targets. Precirix's platform leverages the small size and high affinity of camelid-derived antibody fragments to achieve deep tumor penetration and rapid blood clearance, which is intended to improve the therapeutic index by minimizing radiation exposure to healthy tissues. While the specific molecular target and primary disease indication remain undisclosed, the agent is part of a broader pipeline of single-domain antibody-based radiopharmaceuticals designed for the treatment of solid tumors.